PureTech Founded Entity Vor Bio Announces New Clinical Data Validating Approach of ...
Vor Bio's Phase 1/2 VBP101 study shows trem-cel + Mylotarg reliable engraftment, shielding, broadened therapeutic window, and patient benefit in relapsed/refractory AML. VCAR33ALLO and new asset VADC45 show potential in oncology, gene therapy, and autoimmune disorders.
Reference News
PureTech Founded Entity Vor Bio Announces New Clinical Data Validating Approach of ...
Vor Bio's Phase 1/2 VBP101 study shows trem-cel + Mylotarg reliable engraftment, shielding, broadened therapeutic window, and patient benefit in relapsed/refractory AML. VCAR33ALLO and new asset VADC45 show potential in oncology, gene therapy, and autoimmune disorders.
CMN Weekly (13 September 2024) - Your Weekly CRISPR Medicine News
Vor Bio announces positive Phase 1/2 VBP101 trial data of trem-cel followed by anti-CD33.